CDEK
← All drugs Report issue

survodutide

Peptideexperimental

Clinical trial activity

29 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
17
Phase 2
12
Phase 3
8
Phase 4
0

Earliest trial started Aug 8, 2017 (NCT03175211)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bi 456906

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07206290Phase 2Mar 2, 2026University of Groningen
NCT07221591Phase 1Nov 5, 2025Boehringer Ingelheim
NCT07071974Phase 1Jul 28, 2025Boehringer Ingelheim
NCT06772532Phase 1Feb 10, 2025Boehringer Ingelheim
NCT06745284Phase 1Jan 17, 2025Boehringer Ingelheim
NCT06632444Phase 3Oct 2, 2024Boehringer Ingelheim
NCT06632457Phase 3Oct 2, 2024Boehringer Ingelheim
NCT06564441Phase 1Sep 5, 2024Boehringer Ingelheim
NCT06492135Phase 1Jul 15, 2024Boehringer Ingelheim
NCT06352411Phase 1May 8, 2024Boehringer Ingelheim
NCT06352424Phase 1Apr 15, 2024Boehringer Ingelheim
NCT06309992Phase 3Mar 13, 2024Boehringer Ingelheim
NCT06200467Phase 1Mar 4, 2024Boehringer Ingelheim
NCT06214741Phase 3Feb 6, 2024Boehringer Ingelheim
NCT06176365Phase 3Dec 19, 2023Boehringer Ingelheim
NCT05896384Phase 1Dec 7, 2023Boehringer Ingelheim
NCT06077864Phase 3Nov 17, 2023Boehringer Ingelheim
NCT06066528Phase 3Nov 15, 2023Boehringer Ingelheim
NCT06066515Phase 3Nov 15, 2023Boehringer Ingelheim
NCT05202353Phase 1Mar 15, 2023Boehringer Ingelheim
Showing 20 of 29 trials
Page 1 / 2

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit282832017
University of GroningenAcademic/Hospital1112026
Zealand PharmaFor profit1012022
3 organizations
Page 1 / 1